UNION therapeutics to present at 7th Annual Dermatology Drug Development Summit in Boston

25 Oct 2023
www.biospace.com
HELLERUP, Denmark, Oct. 25, 2023 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D. Kjøller, CEO of UNION therapeutics will present at the seminar on clinical trials at the 7th Annual Dermatology Drug Development Summit on October 31 - November 2, 2023, in Boston, US. Dr. Kjøller will discuss recent challenges and progress in assessing efficacy in clinical trials of hidradenitis suppurativa (HS) and how novel endpoints may improve the approach. To perspectivize the discussion, data from the OSIRIS, proof-of-concept study of oral orismilast in HS presented at the European Academy of Dermatology and Venerology (EADV) Congress 2023 will be presented. 7th Annual Dermatology Drug Development Summit Presentation: Demonstrating efficacy in clinical trials with novel and meaningful endpoints Presenter: Dr. Kim D. Kjøller, CEO, UNION therapeutics Date and time: Wednesday November 1, 2023, at 10:40am EST. Contacts Morten Boesen, Chief Financial Officer, UNION therapeutics A/S +45 2381 5487 morten.boesen@uniontherapeutics.com Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S +45 5385 3044 stj@uniontherapeutics.com About UNION therapeutics UNION therapeutics is a privately held, mid- to late-stage, pharmaceutical development company advancing novel treatment options within immunology and infectious diseases. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at View original content: SOURCE UNION therapeutics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.